Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. MU
5. META
6. FDX
7. IBM
8. PRIM
9. ACN
10. USO

Go back to Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

Myriad Genetics (MYGN) Tops Q4 EPS by 21c

August 3, 2021 7:26 AM EDT

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.12, $0.21 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $189.4 million versus the consensus estimate of $165.4 million.

This was another solid quarter for Myriad Genetics as we delivered strong revenue growth and... More